Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4718-4726

  Liu, Ping ^a   Mould, Diane R ^b  

^a PFIZER INC   (United States)

^b Projections Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN; VORICONAZOLE;

ADOLESCENT; ADULT; AGE; AGED; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS; BIOAVAILABILITY; BLOOD; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; HALF LIFE TIME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICROBIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; VERY ELDERLY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; AREA UNDER CURVE; ASPERGILLOSIS; ASPERGILLUS; BIOLOGICAL AVAILABILITY; BODY WEIGHT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ECHINOCANDINS; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROSPECTIVE STUDIES; VORICONAZOLE;

EID: 84905382594     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02808-13     Document Type: Article

References (25)

1. Theuretzbacher U, Ihle F, Derendorf H. 2006. Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 45:649-663. http://dx.doi.org/10.2165/00003088-200645070-00002.
2. Vazquez JA. 2005. Anidulafungin: a new echinocandin with a novel profile. Clin. Ther. 27:657-673. http://dx.doi.org/10.1016/j.clinthera.2005.06.010.
3. Dowell JA, Schranz J, Baruch A, Foster G. 2005. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J. Clin. Pharmacol. 45:1373-1382. http://dx.doi.org/10.1177/0091270005281234.
4. Dannaoui E, Lortholary O, Dromer F. 2004. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob. Agents Chemother. 48:970-978. http://dx.doi.org/10.1128/AAC.48.3.970-978.2004.
5. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. 2002. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 46:3039-3041. http://dx.doi.org/10.1128/AAC.46.9.3039-3041.2002.
6. Philip A, Odabasi Z, Rodriguez J, Paetznick VL, Chen E, Rex JH, Ostrosky-Zeichner L. 2005. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob. Agents Chemother. 49:3572-3574. http://dx.doi.org/10. 1128/AAC.49.8.3572-3574.2005.
7. Petraitis V, Petraitiene R, Hope WW, Meletiadis J, Mickiene D, Hughes JE, Cotton MP, Stergiopoulou T, Kasai M, Francesconi A, Schaufele RL, Sein T, Avila NA, Bacher J, Walsh TJ. 2009. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob. Agents Chemother. 53:2382-2391. http://dx.doi.org/10.1128/AAC.00329-09.
8. Marr KA, Schlamm HT, Rottinghaus ST, Jagannatha S, Bow EJ, Wingard JR, Pappas P, Herbrecht R, Walsh TJ, Maertens J, Mycoses Study Group. 2012. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis, poster LB2812. 22nd Eur Congr. Clin. Microbiol. Infect. Dis., London, United Kingdom.
9. Liu P, Mould DR. 2014. Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Antimicrob. Agents Chemother. 58:4727-4736. http://dx.doi.org/10. 1128/AAC.02809-13.
10. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. 2002. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553. http://dx.doi.org/10.1128/AAC.46.8.2546-2553.2002.
11. Alebic-Kolbah T, Modesitt MS. 2012. Anidulafungin-challenges in development and validation of an LC-MS/MS bioanalytical method validated for regulated clinical studies. Anal. Bioanal. Chem. 404:2043-2055. http://dx.doi.org/10.1007/s00216-012-6272-4.
12. Andrews E, Damle BD, Fang A, Foster G, Crownover P, LaBadie R, Glue P. 2008. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. Br. J. Clin. Pharmacol. 65:531-539. http://dx.doi.org/10.1111/j.1365-2125.2007.03084.x.
13. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. 2004. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol. 44:590-598. http://dx.doi.org/10.1177/ 0091270004265644.
14. Friberg LE, Ravva P, Karlsson MO, Liu P. 2012. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob. Agents Chemother. 56:3032-3042. http://dx.doi.org/10.1128/AAC.05761- 11.
15. Mould DR, Upton RN. 2013. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst. Pharmacol. 2:e38. http://dx.doi.org/10.1038/psp.2013.14.
16. Glantz SA, Slinker BK. 1990. Primer of applied regression and analysis of variance. McGraw Hill, New York, NY.
17. Karlsson MO, Savic RM. 2007. Diagnosing model diagnostics. Clin. Pharmacol. Ther. 82:17-20. http://dx.doi.org/10.1038/sj.clpt.6100241.
18. Liu P. 2013. Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections. Antimicrob. Agents Chemother. 57:466-474. http://dx.doi.org/10.1128/AAC.01473-12.
19. Damle B, Varma MV, Wood N. 2011. Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use. Antimicrob. Agents Chemother. 55:5172-5177. http://dx.doi.org/ 10.1128/AAC.00423-11.
20. Wood N, Tan K, Purkins L, Layton G, Hamlin J, Kleinermans D, Nichols D. 2003. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br. J. Clin. Pharmacol. 56(Suppl 1):56-61. http://dx.doi.org/10.1046/j.1365- 2125.2003.02000.x.
21. Driscoll TA, Yu LC, Frangoul H, Krance RA, Nemecek E, Blumer J, Arrieta A, Graham ML, Bradfield SM, Baruch A, Liu P. 2011. Comparison of pharmacokinetics and safety of voriconazole intravenousto-oral switch in immunocompromised children and healthy adults. Antimicrob. Agents Chemother. 55:5770-5779. http://dx.doi.org/10.1128/AAC.00531-11.
22. Han K, Capitano B, Bies R, Potoski BA, Husain S, Gilbert S, Paterson DL, McCurry K, Venkataramanan R. 2010. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob. Agents Chemother. 54:4424-4431. http://dx.doi.org/10.1128/AAC.00504-10.
23. Driscoll TA, Frangoul H, Nemecek ER, Murphey DK, Yu LC, Blumer J, Krance RA, Baruch A, Liu P. 2011. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. Antimicrob. Agents Chemother. 55:5780-5789. http://dx.doi.org/ 10.1128/AAC.05010-11.
24. Dickmeyer NJ, Kiel PJ. 2011. Dosing voriconazole in an obese patient. Clin. Infect. Dis. 53:745. http://dx.doi.org/10.1093/cid/cir511.
25. Pai MP, Lodise TP. 2011. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob. Agents Chemother. 55:2601-2605. http://dx.doi.org/10.1128/AAC.01765-10.